Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Orygen Youth Health Research Centre and Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville, VIC 3052, Australia (Австралия) 2 School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia (Австралия) 3 Lipid Disorders Clinic, Metabolic Research Centre and Department of Internal Medicine, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia (Австралия) 4 Queensland Brain Institute, University of Queensland and Queensland Centre for Mental Health Research, Park Centre for Mental Health, St. Lucia, QLD, Australia (Австралия) 5 St Vincent’s Hospital, Melbourne and Department of Psychiatry, University of Melbourne, VIC, Australia (Австралия) 6 Discipline of Psychiatry, School of Medicine, University of Adelaide and Ramsay Health Care, Mental Health Services and Northern Adelaide Local Health Network, Adelaide, SA, Australia (Австралия)
Список исп. литературыСкрыть список 1. Rouillon F, Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur Psychiatry 2005;20(Suppl. 4):S345-8. 2. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004;184(Suppl. 47):S64-6. 3. Cohen D, De Hert M. Endogenic and iatrogenic diabetes mellitus in drug-na€ıve schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm. Neuropsychopharmacology 2011;36:2368-9. 4. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-natıve schizophrenia patients. Neuropsychopharmacology 2010;35:1997-2004. 5. Meltzer HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin 1997;14:1-20. 6. Hollingworth SA, Siskind DJ, Nissen LM et al. Patterns of antipsychotic medication use in Australia 2002–2007. Aust N Z J Psychiatry 2010;44:372-7. 7. Bobo WV, Cooper WO, Stein CM et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013;70:1067-75. 8. Baker RA, Pikalov A, Tran QV et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 2009;42:11-31. 9. DuMouchel W, Fram D, Yang X et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data mining analysis of the FDA adverse event reporting system (1968–2004). Ann Clin Psychiatry 2008;20:21-31. 10. Smith M, Hopkins D, Peveler RC et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008;192:406-11. 11. Eapen V, Shiers D, Curtis J. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication. Aust N Z J Psychiatry 2013;47:435-42. 12. Bonfioli E, Berti L, Goss C et al. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 2012;12:78. 13. Fiedorowicz JG, Miller DD, Bishop JR et al. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev 2012;8:25-36. 14. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspectives. Nat Rev Endocrinol 2011;8:228-36. 15. Manzella D. Top 7 risk factors for type 2 diabetes. http://diabetes.about.com. 16. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry 2004;184(Suppl. 47):S87-93. 17. Haddad PM. Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry 2004;184(Suppl. 47):S80-6. 18. Morgan VA, Waterreus A, Jablensky A et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012;46:735-52. 19. Castle DJ, Jablensky A, McGrath JJ et al. The Diagnostic Interview for Psychoses (DIP): development, reliability and applications. Psychol Med 2006;36:69-80. 20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl. 1):S55-60. 21. Craig CL, Marshall AL, Sjostr € om M et al. International Physical € Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-95. 22. StataCorp. Stata Statistical Software: Release 12. College Station: StataCorp LP, 2011. 23. IBM Corp. IBM SPSS Statistics for Windows, Version 21.0. Armonk: IBM Corp, 2012. 24. International Diabetes Institute. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) Report 2000. www.bakeridi.edu.au. 25. Diabetes Australia. Best practice guidelines for health professionals. www.diabetesaustralia.com.au. 26. International Physical Health in Youth Stream. Healthy Active Lives (HeAL) consensus statement. www.iphys.org.au. 27. Osborn DP, Levy G, Nazareth I et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry 2007;64:242-9. 28. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390-9. 29. Daumit GL, Dickerson FB, Wang NY et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594-602. 30. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9. 31. Galletly CA, Foley DL, Waterreus A et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012;46: 753-61. 32. Heideman WH, Middelkoop BJ, Nierkens V et al. Changing the odds. What do we learn from prevention studies targeted at people with a positive family history of type 2 diabetes? Prim Care Diabetes 2011;5:215-21. 33. Yood MU, DeLorenze G, Quesenberry CP, Jr. et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18:791-9. 34. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl. 2):S12-21. 35. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl. 1):4-17. 36. Nielsen J, Correll CU, Manu P et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 2013;74:603-13. 37. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56. 38. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609-16. 39. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B et al. - Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008;22:547-62. 40. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. http://whqlibdoc.who.int. 41. Lambert BL, Cunningham FE, Miller DR et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81. 42. Vancampfort D, Wampers M, Mitchell AJ et al. A meta-analysis of cardio-metabolic abnormalities in drug natıve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240-50. 43. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012;380:601-10. 44. Valdez R. Detecting undiagnosed type 2 diabetes: family history as a risk factor and screening tool. J Diabetes Sci Technol 2009;3: 722-6. 45. Rabi DM, Padwal R, Tobe SW et al. Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. CMAJ 2013;185:963-7.